Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation

Abstract

At 24 months, IVB is more effective than PDT in treating mCNV. The enlargement of the CRA might be related to the incomplete visual recovery after PDT.

Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization

“…6,7 Recent studies have also reported that anti-VEGF therapy with intravitreal bevacizumab appeared to result in better efficacy in terms of visual improvement compared with PDT. 31,32 Baba et al 31 compared the 2-year outcome of intravitreal bevacizumab with PDT. It was shown that there was no significant change in vision following PDT, while intravitreal bevacizumab resulted in significant visual improvement at 2 years.…”

“…The likely reason for the inferior visual outcome associated with PDT was likely to be due to the enlargement of chorioretinal atrophy around the CNV following PDT. 31 Yoon et al 32 also evaluated the use of anti-VEGF therapy with intravitreal bevacizumab or ranibizumab, PDT, and combined anti-VEGF with PDT in the treatment of myopic CNV. Results at 12 months showed that significantly higher proportion of patients in the anti-VEGF group lost fewer than 15 letters compared with both the combination and the PDT groups.…”

Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization

“…6 Because of the poor natural history of mCNVs, several procedures have been tried to treat mCNVs, for example, thermal laser photocoagulation, 7 photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Pharma AG, Basel, Switzerland), 8 and intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA, USA), a recombinant humanized monoclonal anti-VEGF antibody. Earlier case series have reported good visual outcomes 1 to 2 years after intravitreal bevacizumab (IVB), [9][10][11][12][13][14][15][16][17][18][19][20][21] and at present IVB would be the first-line therapy for sub-and juxtafoveal mCNVs. 22 However, there is still not enough information to predict the visual outcome of each patient with mCNV treated with IVB.…”

Photodynamic therapy: current role in the treatment of chorioretinal conditions

“…25 More recent clinical trials have, however, demonstrated that anti-VEGF therapy achieves much better visual outcomes for myopic CNV than vPDT therapy. [26][27][28] Anti-VEGF therapy is currently the standard of care for treating myopic CNV. 29 vPDT therapy has been used as a treatment for other causes of CNV with variable outcomes.…”